Study for severe to very severe COPD patients

New Study for People with Severe to Very Severe COPD

This research study is testing whether a new investigational drug that targets eosinophils (a type of white blood cell) could help patients with COPD (chronic obstructive pulmonary disease) control symptoms and reduce exacerbations (flare-ups) that lead to hospitalizations. The new investigational drug will be compared to oral and inhaled corticosteroids, the current standard of care for COPD.

More about the study:

  • The study drug (Benralizumab) is administered by Subcutaneous (under the skin) injection (SC).
  • There will be 3794 participants in this trial

If you are interested, please find the full study details and eligibility criteria listed here.

Eligibility Criteria:

Participants must:

  • be between 40 – 85 years old
  • have been diagnosed by a medical professional as having severe to very severe COPD
  • be a current smoker or former smoker

Participants must not:

  • be taking any steroid medications by mouth on a regular basis
  • have been diagnosed with any type of cancer (except skin or cervical) within the past 5 years.

Please complete the online questionnaire to check if you’re eligible for the trial.

If you’re not familiar with clinical trials, here are some FAQs:

What are clinical trials?

Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.

Why participate in a clinical trial?

You will have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.

Learn why I’m talking about Clinical Trials

Leave a Reply

Your email address will not be published. Required fields are marked *

*

Translate »